Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dapagliflozin Performance In Phase III Leaves Concerns,Particularly About Urinary Infections

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Phase III results for Bristol-Myers Squibb/AstraZeneca’s dapagliflozin released at the 2010 American Diabetes Association meeting are raising questions about whether the SGLT-2 inhibitor and others like it have a chance at competing for a second-line role against DPP-4 inhibitors, despite worrisome urinary infection side effects.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts